Clinical Trial Update: A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder. [Phase 3]

View source ↗

Summary

Phase 3 long-term study of SM-13496 in patients with Bipolar I Disorder has completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• SM-13496

Snippet

Sponsor: Sumitomo Pharma Co., Ltd. | Conditions: Bipolar I Disorder | Phase 3 | Status: COMPLETED | Results posted: 2019-07-23